Journal
TRENDS IN PARASITOLOGY
Volume 34, Issue 10, Pages 843-860Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.pt.2018.07.011
Keywords
-
Categories
Funding
- National Institutes of Health [R01GM101183]
- T32 Post Doctoral Fellowship [AI07509]
- NIH [R01 HL130488]
Ask authors/readers for more resources
Despite the recent successes of artemisinin-based antimalarial drugs, many still die from severe malaria, and eradication efforts are hindered by the limited drugs currently available to target transmissible gametocyte parasites and liver-resident dormant Plasmodium vivax hypnozoites. Host-targeted therapy is a new direction for infectious disease drug development and aims to interfere with host molecules, pathways, or networks that are required for infection or that contribute to disease. Recent advances in our understanding of host pathways involved in parasite development and pathogenic mechanisms in severe malaria could facilitate the development of host-targeted interventions against Plasmodium infection and malaria disease. This review discusses new opportunities for host-targeted therapeutics for malaria and the potential to harness drug polypharmacology to simultaneously target multiple host pathways using a single drug intervention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available